# Genor Biopharma Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genor-biopharma-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.genorbio.com
- Total disclosed funding: $160M
- Latest round: Series B (Jun 1, 2020)
- Investors on record: 4

## About

Based in China, Genor Biopharma Co.,Ltd. focuses on the development and commercialization of innovative biopharmaceutical products, primarily targeting antibody therapies for various diseases.Genor Biopharma Co.,Ltd. specializes in biopharmaceutical development and was founded in 2007 in Shanghai, China. The company was involved in a MERGER in October 2020, raising USD 677.00 mn from Edding Genor Group Holdings Limited. The firm has completed a total of 9 deals, with the most recent deal dated October 7, 2020. The CEO is Feng Guo, who has a history of leadership in the biopharmaceutical sector.Genor Biopharma Co. Ltd specializes in developing and commercializing biopharmaceutical products, particularly innovative monoclonal antibody therapies aimed at treating diseases such as cancer and autoimmune disorders. Their products are designed to engage specific biological targets to enhance therapeutic efficacy while minimizing adverse effects. Genor serves a global customer base, including hospitals and pharmaceutical distributors, with products marketed across North America, Europe, and Asia.In 2020, Genor Biopharma Co. Ltd generated revenue of USD 1,497,981.40, with an EBITDA of -USD 119,932,484.50 for the year.Genor Biopharma Co. Ltd plans to launch new products focused on innovative monoclonal antibodies, with specific details expected in upcoming announcements. The company aims to expand into new markets, particularly in Europe and North America, by the end of 2023. The funds raised during the recent IPO, amounting to HKD 2.8776 billion, will support these initiatives and enhance their product pipeline in preparation for broader market entry.

## Funding rounds

- Series B, Jun 1, 2020, $160M — Temasek Holdings, Haitong Capital, Hillhouse Investment, CR Capital

## Investors

- Temasek Holdings — Series B
- Haitong Capital (https://capitalatlas.ai/funds/haitong-capital) — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series B